In a substantial step towards regulatory advancement, the Pharmacy and Poisons Board has formalized a strategic partnership with the US Food and Drug Administration (USFDA) by signing a Confidentiality Commitment.
This important agreement, sealed on March 15th, 2024, in Washington D.C., comes after a week of significant progress for PPB in the regulation of Medical Devices and Diagnostics.
Dr. Fred Siyoi, the Chief Executive Officer CEO of PPB, and Mark Abdoo, Associate Commissioner for Global Policy and Strategy at the US FDA, affirmed their commitment to regulatory excellence through this collaborative framework.
This engagement underscores PPB’s proactive approach to enhancing regulatory standards and fostering international cooperation.
The Confidentiality Commitment signifies a significant step towards establishing a collaborative framework between PPB and the US FDA, facilitating the exchange of critical information and promoting regulatory harmonization in the field of medical devices and diagnostics.
About Pharmacy and Poisons Board
The Pharmacy and Poisons Board is the Drug Regulatory Authority established under the Pharmacy and Poisons Act, Chapter 244 of the Laws of Kenya.
The Board regulates the Practice of Pharmacy and the Manufacture and Trade in drugs and poisons.
It also aims to implement the appropriate regulatory measures to achieve the highest standards of safety, efficacy and quality for all drugs, chemical substances and medical devices, locally manufactured, imported, exported, distributed, sold, or used, to ensure the protection of the consumer as envisaged by the laws regulating drugs in force in Kenya
